Aug 12, 2023, 15:49
Stephen V Liu: Editorial New England Journal of Medicine from Dr. Christine Lovly, gives nice perspective on the phase III KEYNOTE 671 study in resectable non-small-cell lung cancer
As per Stephen V. Liu, the Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, in a tweet, he mentions that the “Editorial New England Journal of Medicine from Dr. Christine Lovly, gives nice perspective on the phase III KEYNOTE 671 study in resectable NSCLC. Perioperative immunotherapy provides clear benefit but many ?s remain – especially regarding the need to continue IO and an MRD test.”
For the article: click here
Source: Stephen V Liu / Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 07:34
Apr 18, 2025, 07:22
Apr 18, 2025, 07:02
Apr 18, 2025, 06:58
Apr 18, 2025, 06:50
Apr 18, 2025, 03:14